0.97
+5.09%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ocugen
From its filings with the US Securities and Exchange Commission
Ocugen is based in Malvern, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker OCGN. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $4.4m and a net loss of $67.8m. At that date it held total assets of $43.5m and shareholders' equity of −$12.2m.
Ocugen is aiming to redefine the future of vision through game-changing gene therapies with the potential to address significant, unmet medical needs. Our First-in-class, breakthrough modifier gene therapy platform presents a potential paradigm shift in treating inherited retinal diseases and blindness diseases affecting millions across the globe.
We have completed enrollment in the Phase 3 liMeliGhT clinical trial for OCU400. Positive long-term, 3-year Phase 1/2 durable, safety and tolerability data for OCU400 demonstrate sustained clinically meaningful, approximately 2-line luminance visual acuity ("LLVA") gain, reinforcing durable gene-agnostic benefits. Positive long-term, 3-year Phase 1/2 data for OCU400 were recently assessed in evaluable subjects and builds on prior 2-year results showing consistent clinically meaningful, approximately 2-line LLVA gain across mutations. OCU400 maintained a favorable durability, safety and tolerability profile with no new treatment-related serious adverse events or adverse events of interest emerged.
We are on track to begin a rolling BLA submission in the third quarter of 2026. Topline Phase 3 data expected in the first quarter of 2027, advancing OCU400 towards potential approval in 2027 as a treatment option for early- to late-stage RP.
Quoted from its 10-K, filed 4 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Dec 2014
- Employees
- 116
- Website
- histogenics.com ↗
- Head office
- 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Shankar MusunuriChairman of the Board, Chief Executive Officer, since 2019$1.9m
- Mr. Ramesh RamachandranChief Accounting Officer
- Dr. Arun UpadhyayChief Scientific Officer, Head of Research and Development$870,869
- Dr. Huma QamarChief Medical Officer$1.7m
- Ms. Kirsten CastilloIndependent Director$114,761
- Dr. Uday KompellaIndependent Director$101,636
- Mr. Junge ZhangIndependent Director$86,636
- Ms. Tiffany HamiltonHead of Communications, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 49
- Social
- 68
- Governance
- 31
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovative Technology: Ocugen Inc has developed an innovative technology platform that focuses on novel biologics for treating various diseases.
- Strategic Partnerships: The company has established strategic partnerships with leading pharmaceutical companies, enabling access to resources, expertise, and global distribution networks.
- Strong R&D Capabilities: Ocugen Inc possesses strong research and development capabilities, allowing them to constantly innovate and develop new therapeutic solutions.
Weaknesses
- Limited Product Portfolio: Currently, Ocugen Inc has a limited product portfolio, with only a few candidates in advanced stages of development.
- Reliance on Partnerships: The company heavily relies on strategic partnerships for funding, manufacturing, and commercialization. This reliance may limit their independence and control over key aspects of the business.
- Regulatory Challenges: The biopharmaceutical industry is subject to strict regulations, and any delays or failures in obtaining regulatory approvals could impact Ocugen Inc's ability to bring its products to market.
Opportunities
- Market Expansion: Ocugen Inc can explore untapped markets and expand its reach geographically to maximize its revenue potential.
- Growing Demand: The global demand for innovative biologics is increasing, providing an opportunity for Ocugen Inc to capture a larger market share.
- Collaborative Research: Collaboration with academic institutions, research organizations, and other industry players can provide avenues for knowledge-sharing, resource pooling, and expanding the company's research capabilities.
Threats
- Intense Competition: The biopharmaceutical industry is highly competitive, with numerous established players and new entrants. Ocugen Inc may face challenges in differentiating itself and capturing market share.
- Economic Volatility: The company's financial performance and growth prospects can be impacted by economic downturns, currency fluctuations, and other macroeconomic factors beyond their control.
- Intellectual Property Risks: Protecting intellectual property rights is crucial for Ocugen Inc. Any unauthorized use or infringements could undermine their competitive position and lead to revenue losses.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.